Microchip Technology Incorporated (MCHP) Q1 2026 Earnings Call Transcript

Microchip Technology (MCHP) reported robust Q1 FY26 results, with net sales up 10.8% sequentially to $1.075 billion and non-GAAP EPS of $0.27, both exceeding guidance, attributed to a broad-based inventory correction across distributors and direct customers. The company significantly reduced inventory days to 214 from 251, with corresponding decreases in inventory write-offs and underutilization charges, contributing to a non-GAAP gross margin of 54.3%. For Q2 FY26, MCHP guided for continued above-seasonal sequential sales growth of 5.1% to $1.13 billion and anticipates non-GAAP gross margins to improve to 55-57%. Management highlighted lengthening lead times on certain products, indicating further customer inventory depletion, and affirmed that increasing free cash flow post-Q2 will be primarily directed towards debt reduction, prioritizing deleveraging from 4.22x net debt to EBITDA over near-term share buybacks.

Analysis

Microchip Technology (MCHP) delivered a robust Q1 fiscal 2026, with net sales growing 10.8% sequentially to $1.075 billion, exceeding guidance. This performance was driven by a broad-based recovery as the inventory correction cycle matures, a dynamic management terms the "trifecta effect" of normalizing inventory at direct customers, distributors, and their end customers. The gap between distributor sell-through and sell-in narrowed significantly from $103 million in the prior quarter to $49.3 million, indicating that replenishment activity is accelerating but has further to run. A key operational highlight was the rapid inventory reduction, with on-hand inventory falling by $124 million and inventory days dropping from 251 to 214. While reported non-GAAP gross margin was 54.3%, it was suppressed by $128.6 million in combined inventory write-offs and factory underutilization charges; excluding these, the underlying product gross margin stands at a strong 66.3%, signaling significant latent profitability. The outlook remains positive, with Q2 revenue guided to grow 5.1% sequentially to $1.13 billion, well above seasonal trends, supported by the strongest monthly bookings in three years. Management anticipates this above-seasonal growth will persist, and expects to begin increasing wafer starts in the December quarter to pre-empt future shortages as lead times on some products are already beginning to extend.

Key Decisions for Investors

• Investors should recognize the strong sequential growth and above-seasonal guidance as confirmation that MCHP's cyclical recovery is underway, with further upside potential as the company is still shipping below normalized end-market demand.
• Monitor the reduction in inventory write-offs and underutilization charges, as their continued decline is the primary catalyst for unlocking significant gross margin expansion towards the company's 65% long-term target, which will heavily leverage the bottom line.
• Pay attention to lengthening product lead times, which serve as a leading indicator of a tightening market and support the thesis that the inventory destocking phase is ending.
• Note that capital allocation is firmly prioritized towards debt reduction, given the high net debt to EBITDA ratio of 4.22; expect excess free cash flow to be used for deleveraging rather than share buybacks in the near term.